Entrada Therapeutics, Inc.
TRDA
$7.46
$0.010.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -165.78M | -166.12M | -143.75M | -103.46M | -73.35M |
| Total Depreciation and Amortization | 3.76M | 3.96M | 4.10M | 4.20M | 3.91M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.00M | 16.39M | 15.94M | 14.41M | 11.68M |
| Change in Net Operating Assets | 10.34M | 14.08M | -4.80M | -43.07M | -66.10M |
| Cash from Operations | -134.67M | -131.70M | -128.51M | -127.91M | -123.87M |
| Capital Expenditure | 323.00K | 59.00K | -1.04M | -1.88M | -2.69M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 159.84M | 138.95M | 117.85M | 142.94M | 11.71M |
| Cash from Investing | 160.16M | 139.01M | 116.81M | 141.05M | 9.02M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 650.00K | 637.00K | 887.00K | 2.10M | 2.09M |
| Repurchase of Common Stock | -- | -- | -- | -- | -11.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 650.00K | 637.00K | 887.00K | 2.10M | 2.08M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.14M | 7.95M | -10.82M | 15.24M | -112.77M |